Antibiotics for the Treatment of Patients with Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacterial Infections
Antibiotics · 04.09.2025 · 14 (9) · 894
DOI: 10.3390/antibiotics14090894 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 04.09.2025. Verfasst von Matthew E Falagas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Infections caused by MBL-producing Gram-negative bacterial pathogens have disseminated worldwide and are associated with considerable morbidity and mortality. We evaluated the published clinical evidence on the use of various antibiotics for the treatment of patients with such infections. The available data suggest the consideration of the new antibiotics cefiderocol and aztreonam-avibactam for the treatment of patients with infections caused by MBL-producing Gram-negative bacterial pathogens. However, their considerable cost and limited availability hinder their use. Also, the combination of ceftazidime-avibactam and aztreonam has been occasionally used, especially when there was an unavailability of aztreonam-avibactam. Additionally, old antibiotics such as colistin and fosfomycin, especially in combination antimicrobial therapy, may be considered for the treatment of patients with such infections. The relevant clinical data on the use of tigecycline and aminoglycosides for infections caused by MBL-producing pathogens are limited. Thus, the evaluation of the published evidence suggests the best treatment options for the treatment of patients with such infections at present. Also, the limited available data highlight the need for dissemination of the already acquired clinical experience and the conduct of new studies examining currently available antibiotics, as well as investigational antimicrobial agents for the treatment of patients with infections caused by MBL-producing Gram-negative bacterial pathogens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece.
- School of Medicine, European University Cyprus, 6 Diogenous Str., 2404 Nicosia, Cyprus.
- Department of Medicine, Tufts University School of Medicine, Boston, MA 02111, USA.
ORCID-Profile: Dimitrios Ragias
Zitieren
APA
Falagas, M. E., Kontogiannis, D. S., Ragias, D., & Kakoullis, S. A. (2025). Antibiotics for the Treatment of Patients with Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacterial Infections. Antibiotics, 14(9), 894. https://doi.org/10.3390/antibiotics14090894
Vancouver
Falagas ME, Kontogiannis DS, Ragias D, Kakoullis SA. Antibiotics for the Treatment of Patients with Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacterial Infections. Antibiotics. 2025;14(9):894. doi:10.3390/antibiotics14090894
BibTeX
@article{Falagas2025,
author = {Falagas, Matthew E and Kontogiannis, Dimitrios S and Ragias, Dimitrios and Kakoullis, Stylianos A},
title = {Antibiotics for the Treatment of Patients with Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacterial Infections},
journal = {Antibiotics},
year = {2025},
volume = {14},
number = {9},
pages = {894},
doi = {10.3390/antibiotics14090894}
}
EUVIMED